



20x der

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

David J. Grainger et al.

Title:

COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Docket No.:

295.027US1

September 11, 1998

Examiner:

Filed:

Prema Mertz

Serial No.: 09/150,813

Due Date: April 3, 1999 Group Art Unit: 1646

Assistant Commissioner for Patents

Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

RECEIVED

SEP 0 8 1999

TECH CENTER 1600/2900

A return postcard.

A Response to Restriction Requirement and Preliminary Amendment (7 Pages). X X

Petition for Extension of Time (1 pg). X

A check in the amount of \$1850.00 to cover the Extension of Time Fee.

- A Sequence Listing (66 pgs) and a Computer-readable version of Sequence Listing (1 diskette). X
- Copy of Notice to Comply with Requirements re: Sequence Listing. X
- A Communication Under 37 CFR 1.821 (1 pg).

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described above, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Petents, Washington, D.C. 20231, on this 31 day of August, 1999.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Reg. No. 39,665

Customer Number 21186

(GENERAL)



Application No.: 09 150,813

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)

9	
M	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a *Sequence Listing* as required by 37 C.F.R. 1.821(c).
X	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
_	7. Other:
U	
AI X	pplicant Must Provide:  An <u>Initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	•
X	4.925(b) or 1.825(d)
	or questions regarding compliance to these requirements, please contact:
F	or Rules Interpretation, call (703) 308-4216 or CRF Submission Help, call (703) 308-4212 or PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE